$INFI possible gap fill. Needs volume. Not saying today's the day, just one to watch.

Nice to see $CRIS / Roche approval of Hedgehog inhibitor vismodegib in skin cancer after $INFI Hedgehog setback in pancreatic last week

Start your 14 day free trial and read our latest reports on $INFI $DEPO $ARQL $MNTA $ONTY $FOLD and other #biotechs https://t.co/LYqulDtN

$INFI update based on pancreatic cancer trial failure, conference call, and JPM webcast posted to @ChimeraResearch https://t.co/14gyaVJd

Working on $INFI update and $SNMX coverage report (made a recommendation to @ChimeraResearch subscribers today) for this weekend- stay tuned

It's disappointing to see another met pancreatic trial fail. Such a tough indication and patients need more options along with Gem. $INFI

surprised $INFI is holding this strong. who got those shares at $5 while I was driving to work?!

Pre-Market Actives: $INFI $IDIX $AMLN $ACHN

Stocks movers in pre-market $CPHD $INFA $CIGX $KLAC $STX $RVBD $INFI $ABFS $IDIX $FRAN $MRVL

Not shocked $INFI failed in pancreatic caner, but surprised the drug did so bad as to get halted early!

$INFI trading under $5 after trial #FAIL, down 50%